AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02662790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doppler
Study NCT01572090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Changes
Description: Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.~Dietetic and physical activity counselling with a dietitian.
Study NCT02372630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: 5 mg daily oral tablets of linagliptin
Study NCT02372630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo giving orally daily
Study NCT02468778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate PHP
Description: The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
Study NCT02468778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Any Abiomed Impella® device approved for use in high-risk PCI
Description: Any Abiomed Impella® device approved for use in high-risk PCI.
Study NCT00234078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% OPC-12759
Study NCT00234078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPC-12759
Study NCT00234078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% OPC-12759
Study NCT00234078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00649753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Category II Pelvic Blocking
Description: Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction.
Study NCT00649753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Category II Pelvic Blocking and Cranial
Description: Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction. During pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
Study NCT00649753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial Only
Description: Without pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
Study NCT01114022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental 1
Description: oeso pharyngeal device
Study NCT01114022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: oeso pharyngeal device
Study NCT01114022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental 3
Description: oeso pharyngeal device
Study NCT01114022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: oeso pharyngeal device
Study NCT02715622 — intervention group
Intervention type: PROCEDURE
Intervention: Hernia repair
Description: Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice
Study NCT00921622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 1000 IU twice daily for up to 10 days
Study NCT00921622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 500 mg twice daily for up to 10 days
Study NCT04437862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q Revascularization System
Description: Q Revascularization System for mechanical thrombectomy
Study NCT04753710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocular gel
Description: Instillation
Study NCT04753710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ocular gel
Description: Instillation
Study NCT04794322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine lavage, or a wash of the womb
Description: Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis.
Study NCT04794322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Participants undergo two blood draws (one required, one optional) up to 31 days before surgery
Study NCT04794322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pap smear
Description: Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix.
Study NCT01454544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIT Tablet
Description: 1 tablet per day in 12 months
Study NCT01454544 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIT Tablet
Description: 1 tablet per day in 12 months
Study NCT04031131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Instillagel
Description: Topical Anaesthetic Gel (Instillagel) licensed for rectal administration.
Study NCT04031131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: KY Gel
Description: Lubricant Gel
Study NCT04031131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KY Gel
Description: Lubricant Gel
Study NCT00096265 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo radiation therapy once daily for approximately 3 weeks
Study NCT00096265 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo radiation therapy once daily for approximately 3 weeks
Study NCT00096265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given orally
Study NCT00096265 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Patients undergo surgery after radiation therapy
Study NCT00096265 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Patients undergo surgery after radiation therapy
Study NCT00096265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given orally
Study NCT02728102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumor Cell Collection
Description: Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell preparations will be generated. Myeloma cells will be isolated and frozen for subsequent vaccine generation for patients randomized to the vaccine arm (randomization occurs after transplant and recovery).
Study NCT02728102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Cell Collection
Description: Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell preparations will be generated. Myeloma cells will be isolated and frozen for subsequent vaccine generation for patients randomized to the vaccine arm (randomization occurs after transplant and recovery).
Study NCT02728102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cell Transplant
Description: Patients will receive an autologous graft with a minimum cell dose of 2.0 x 10\^6 CD34+ cells/kg patient actual body weight per autologous transplantation.
Study NCT02728102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant
Description: Patients will receive an autologous graft with a minimum cell dose of 2.0 x 10\^6 CD34+ cells/kg patient actual body weight per autologous transplantation.
Study NCT02728102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Autologous hematopoietic cell transplant will be done with high-dose melphalan of 200mg/m\^2 at the schedule and timing according to institutional practices.
Study NCT02728102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Autologous hematopoietic cell transplant will be done with high-dose melphalan of 200mg/m\^2 at the schedule and timing according to institutional practices.
Study NCT02728102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Blood samples will be collected through a catheter in the neck or chest and leukapheresis will be performed using standard clinical procedures.
Study NCT02728102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myeloma vaccine
Description: The target dose is 3 x 10\^6 fusion cells per vaccine. A minimum of 3 x 10\^6 total fusion cells will be required to proceed with vaccine administration. Patients who have \<3 x 10\^6 total fusion cells will not proceed with vaccination. Patients will receive the DC/MM fusion vaccine on day 1 of cycles 2, 3, and 4 of lenalidomide maintenance. Vaccine will be administered by subcutaneous injection in the upper thigh.
Study NCT02728102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: 100 ug GM-CSF will be given subcutaneously in the upper thigh and daily for a total of 4 days of each cycle.
Study NCT02728102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 100 ug GM-CSF will be given subcutaneously in the upper thigh and daily for a total of 4 days of each cycle.
Study NCT02728102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.
Study NCT02728102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.
Study NCT04043884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sEmg biofeedback training
Description: Volunteers will perform scapular strengthening and stabilization exercises added to sEMG biofeedback in the upper trapezius (TS), Trapezius (TM), Lower Trapezius (TI), and Serratil Anterior (AS) muscles in real time displayed in a Computer screen.
Study NCT04043884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: The volunteers will perform a strengthening protocol with elbow flexion exercises, medial and lateral shoulder rotation, scapular retraction and push up plus.
Study NCT03750097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comfortable walking velocity (CWV)
Description: Walking for 250 Steps with self-selected comfortable walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT)
Study NCT03750097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow walking velocity (SWV: CWV - 20%)
Description: Walking for 250 Steps with slow walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Slow walking consists of walking with 20% slower than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
Study NCT03750097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fast walking velocity (FWV: CWV + 20%)
Description: Walking for 250 Steps with fast walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Fast walking consists of walking with 20% faster than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
Study NCT02555111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto
Description: 15mg/day oral administration during 2 to 4 years (based on the recruitment date).
Study NCT01944267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apically positioned flap
Description: Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally.
Study NCT01944267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures
Study NCT01944267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: apically positioned flap with Mucograft
Description: Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures.
Study NCT04135820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-7711
Description: BPI-7711 180 mg
Study NCT02359474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin
Study NCT02359474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Study NCT02359474 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA double-strand breaks
Description: The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and danger signals are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018).
Study NCT02359474 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA double-strand breaks
Description: The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and danger signals are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018).
Study NCT01436422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine - Admixture TV003
Description: One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
Study NCT01436422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine - Admixture TV005
Description: One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
Study NCT01436422 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One subcutaneous injection at Day 0 and Day 180 of placebo
Study NCT02113397 — intervention group
Intervention type: DRUG
Intervention: Colistimethate 75 mg inhaled two times daily
Study NCT00753740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IT-101 (12mg/m2/dose)
Description: Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
Study NCT00753740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IT-101 (15mg/m2/dose)
Description: Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
Study NCT00753740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose (Placebo)
Description: Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
Study NCT00183417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Description: Participants will complete worksheets and group discussion on how to increase positive mood and activity.
Study NCT00183417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive/expressive (S/E) therapy
Description: Participants will be encouraged to express feelings and emotions without advice giving.
Study NCT00183417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bibliotherapy
Description: Participants will be given a book on how to increase their mood.
Study NCT03820739 — intervention group
Intervention type: OTHER
Intervention: Follow-up
Description: No investigational vaccine will be administered during this study
Study NCT03820739 — intervention group
Intervention type: OTHER
Intervention: Blood sample collection
Description: Blood sampling to assess vaccine-induced immune responses will be conducted only in cohort 1 in a subsample consisting of approximately 102 adults and 165 children (55 from each of the three paediatric age groups that were enrolled in EBOVAC-Salone: 12-17 year olds, 4-11 year olds, and 1-3 year olds).
Study NCT02984930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of study drug (esomeprazole, mosapride)
Description: Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.
Study NCT02984930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of study drug (esomeprazole, placebo tablet)
Description: Esomeprazole(Hanxium®) 40 mg once daily and placebo tablets that are identical to mosapride tablets t.i.d (3 times a day) for 4 weeks.
Study NCT02984930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upper endoscopy, scintigraphy
Description: After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.
Study NCT02984930 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: upper endoscopy, scintigraphy
Description: After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.
Study NCT02756429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Patients with atrial fibrillation for whom electrophysiology exploration or ablation are programmed; All blood samples will be taken through the exploration catheter. For the peripheral blood sample, blood will be taken at the introduction of the catheter into the femoral vein. Then the blood samples in the coronary sinus and in the left atrium will be made at progressively exploration.
Study NCT01457352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC0921